What is Febuxostat Tablets 80mg Febustat used for?
Febuxostat Tablets 80mg Febustat belongs to the xanthine oxidase inhibitor class of drugs. It works by inhibiting the production of uric acid in the body. Febuxostat is a medication that is used to prevent gout attacks but not to treat them once they have occurred.
Is it safe to use febuxostat for an extended period of time?
To avoid a gout attack, remember to take febuxostat on a daily basis. It can take up to six months for it to fully work. Even if you have a gout attack, you should continue to take it every day.
Is it okay for me to take febuxostat 80mg twice a day?
Febuxostat Tablets 80mg Febustat is a once-daily medication. Most patients start with one 80mg tablet per day. The dose can be increased to 80 mg per day if necessary.
What are the Febuxostat Tablets 80mg Febustat symptoms?
- Hyperuricemia is a condition in which the amount of uric acid in your blood is abnormally high. High febuxostat levels can cause a variety of illnesses,
- including gout, a painful form of arthritis.
- Joint discomfort is excruciating.
- The rigidity of the joints
- Affected joints are difficult to move.
- Swelling and redness
- in crooked joints. For more click here
Does Febuxostat Tablets 80 mg Febustat cause a rise in creatinine levels?
Although the Febuxostat Tablets 80mg Febustat group had a lower serum creatinine level, the absolute magnitude of this reduction was minor (0.03 mg/dL).
Is febuxostat toxic to the liver?
Although no cases of acute or chronic liver impairment have been recorded as a result of febuxostat, clinical experience with this drug is limited.
Is it possible that Febuxostat Tablets 80mg Febustat will harm your kidneys?
According to findings published in Arthritis Research & Therapy, the drugs februxostat and allopurinol are linked to an increased risk of acute kidney damage (AKI).
Is febuxostat a blood pressure medication?
According to a retrospective study of febuxostat Phase 3 studies, Febuxostat significantly reduced systolic (SBP) and diastolic (DBP) over 28 weeks in adults with untreated hypertension and gout.
When febuxostat was first approved, warnings that it should not be used in patients with ischemic heart disease or congestive heart failure were included in the product labeling due to pre-market research that revealed it was linked to significant cardiovascular (CV) events.